Key Market Indicator:
F&G: 63
25.143,30 NASDAQ · 49.017,00 DOW · 6.873,90 S&P · 4.671,72 Gold · 63,10 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
© PR Newswire
01.07.2025
ISIN: SE0007692850
Camurus AB
CAMX
LISTED
STO
Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU
Article
News Preview
First subcutaneous, once-monthly octreotide for treatment of acromegalyFor convenient self-administration with a pre-filled autoinjector penLUND, Sweden, July 1, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous depot, marketing authorization* for the ma...
Themefolio
Profiler
Peergroup
© PR Newswire
01.07.2025
ISIN: SE0007692850
Camurus AB
CAMX
LISTED
STO
Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU
Article
News Preview
First subcutaneous, once-monthly octreotide for treatment of acromegalyFor convenient self-administration with a pre-filled autoinjector penLUND, Sweden, July 1, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous depot, marketing authorization* for the ma...
Themefolio
Profiler
Peergroup
© PR Newswire
01.07.2025
ISIN: SE0011205202
Vitrolife AB
VITR
LISTED
STO
Vitrolife Group completes refinancing facility backed by leading Nordic Banks
Article
News Preview
GOTHENBURG, Sweden, July 1, 2025 /PRNewswire/ -- Vitrolife AB (publ) has today renewed and signed a loan agreement of EUR 300 million comprising of term loan and revolving credit facility. The term loan will be used to refinance existing debt and the revolving credit facility will be available for general corporate purposes.  The loan agreement...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
01.07.2025
ISIN: US8793691069
Teleflex Inc
TFX
LISTED
NYSE
Teleflex Completes Acquisition of BIOTRONIK’s Vascular Intervention Business
Article
News Preview
WAYNE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG. The acquisition adds a broad portfolio of therapeutic...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
01.07.2025
ISIN: NL0015000DX5
Atai Life Sciences N.V.
ATAI
LISTED
NASDAQ
atai Life Sciences Announces $50 Million Private Placement Financing
Article
News Preview
Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1 Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, in...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.07.2025
ISIN: NL0015000DX5
Atai Life Sciences N.V.
ATAI
LISTED
NASDAQ
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
Article
News Preview
NEW YORK, and AMSTERDAM and OXFORD, United Kingdom, July 01, 2025 (GLOBE NEWSWIRE) --  atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, and Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage bio...
Themefolio
Profiler
Peergroup
© Newsfile
01.07.2025
ISIN: NL0011832936
Cosmo Pharmaceuticals NV
COPN
LISTED
SIX
Cosmo Unveils Bold 2030 Vision and Strategy; Launches AI-Driven Growth Phase at Investor Day 2025
Article
News Preview
Ad hoc announcement pursuant to Art. 53 LR Company sets ambitious vision for €480 million in recurring revenues and a 40% EBITDA margin by 2030; outlines roadmap for accelerated AI-driven growth and innovation.Dublin, Ireland--(Newsfile Corp. - July 1, 2025) - Cosmo N.V. (SIX: COPN), a global leader in AI-driven h...
Themefolio
Profiler
Peergroup
© BusinessWire
01.07.2025
ISIN: US88023B1035
Tempus AI, Inc.
TEM
LISTED
NASDAQ
Tempus Announces Pricing of Upsized Offering of $650 Million of Convertible Senior Notes
Article
News Preview
Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the pricing of $650 million aggregate principal amount of 0.75% Convertible Senior Notes due 2030 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualif...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
01.07.2025
ISIN: BE0003755692
AGFA Gevaert NV
AGFB
LISTED
EURONEXT
DASA, Latin America's Largest Diagnostic Provider, Selects AGFA HealthCare's Enterprise Imaging Platform in Flagship Agreement
Article
News Preview
AGFA HealthCare is proud to announce a landmark achievement: the adoption of its Enterprise Imaging Platform by the largest integrated health network in Latin America - and the fifth largest globally. MORTSEL, BE / ACCESS Newswire / July 1, 2025 / DASA (Diagnósticos da América S.A.) operates an extensive hospital network across Brazil and...
Themefolio
Profiler
Peergroup
© ActuNews
30.06.2025
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC
Article
News Preview
Leuven, BELGIË – 30 juni 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen: Oxurion ontving een transparanti...
Themefolio
Profiler
Peergroup
© ActuNews
30.06.2025
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
Article
News Preview
Leuven, BELGIUM – June 30, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on June 26, 2025, from Atlas...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
ISIN: DK0060336014
Novozymes A/S
NSIS B
LISTED
CPH
Transactions under Novonesis’ share buyback program
Article
News Preview
Novonesis has now completed the announced share buyback program of B shares worth up to EUR 100 million (DKK 746 million) in total during 2025. As of June 27th, 2025, Novonesis has purchased an accumulated  1,729,099 shares with a transaction value of DKK 745,2 million under the share buyback program announced by Novonesis in Company announcement N...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
30.06.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Publishes Letter to Shareholders
Article
News Preview
OSE Immunotherapeutics Publishes Letter to Shareholders...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
ISIN: BE0003766806
Ion Beam Applications SA
IBAB
LISTED
EURONEXT
IBA – Transparency Notification - Denominator
Article
News Preview
                                                                                                                  June 30th, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
ISIN: DK0060257814
Zealand Pharma A/S
ZEAL
LISTED
CPH
Total number of shares and voting rights in Zealand Pharma as of June 30, 2025
Article
News Preview
Company announcement – No. 16 / 2025...
Themefolio
Profiler
Peergroup
© BusinessWire
30.06.2025
ISIN: US98887Q1040
Zai Lab Limited
ZLAB
LISTED
NASDAQ
Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
Article
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis. Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaning...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
ISIN: DK0010272202
Genmab A/S
GMAB
LISTED
CPH
Completion of Share Buy-back Program
Article
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© PR Newswire
30.06.2025
ISIN: GB00BN4HT335
Indivior PLC
INDV
LISTED
NASDAQ
Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes
Article
News Preview
RICHMOND, Va., June 30, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) will be added as a member of the U.S. small-cap Russell 2000® Index, effective after the U.S. market opens today as part of the 2025 Russell indexes reconstitution. The annual reconstitution of the Russell U.S. indexes captures the 4,000 largest U.S. stocks as of April...
Themefolio
Profiler
Peergroup
© BusinessWire
30.06.2025
ISIN: US88023B1035
Tempus AI, Inc.
TEM
LISTED
NASDAQ
Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense
Article
News Preview
Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its intent to offer, subject to market conditions and other factors, $400 million aggregate principal amount of Convertible Senior Notes due in 2030 (the “Notes”) in a private placement (the “Off...
Themefolio
Profiler
Peergroup
© BusinessWire
30.06.2025
ISIN: FR0014000MR3
Eurofins Scientific SE
ERF
LISTED
EURONEXT
Eurofins Scientific SE: Director/PDMR Shareholding
Article
News Preview
Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
ISIN: US15102K1007
Celcuity Inc
CELC
LISTED
NASDAQ
Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib
Article
News Preview
• In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”),the six-month radiographic progression free survival (“rPFS”) rate was 66%...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
ISIN: SE0002190926
Karolinska Development AB
KDEV
LISTED
STO
Karolinska Development divests shares in portfolio company OssDsign
Article
News Preview
STOCKHOLM, SWEDEN, June 30, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) divests its remaining shares in the portfolio company OssDsign and thereby strengthens the investment company’s liquidity. The divestments brings Karolinska Development a capital injection of approximately SEK 34.5 million....
Themefolio
Profiler
Peergroup
© PR Newswire
30.06.2025
ISIN: SE0002148817
Hansa Biopharma AB
HNSA
LISTED
STO
Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London
Article
News Preview
LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled analysis including data from the 17-HMedIdeS-14 study, an international long-term follow-up study of patients who have received a kidney transplant following desensitization with imlif...
Themefolio
Profiler
Peergroup
© PR Newswire
30.06.2025
ISIN: SE0002148817
Hansa Biopharma AB
HNSA
LISTED
STO
Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London
Article
News Preview
LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled analysis including data from the 17-HMedIdeS-14 study, an international long-term follow-up study of patients who have received a kidney transplant following desensitization with imlif...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.06.2025
ISIN: GB0009223206
Smith & Nephew PLC
SN
LISTED
LSE
Global Sports Medicine leader Smith+Nephew to sponsor select players competing at Wimbledon, highlighting advanced solutions for joint repair
Article
News Preview
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces it will once again support select players during high profile matches at The Championships, Wimbledon in 2025. The world’s oldest and most prestigious tennis tournament serves as a perfect backdrop to showcase Smith+Nephew’s purpose of ‘Life Unlimited’ - making a diff...
Themefolio
Profiler
Peergroup
© PR Newswire
28.06.2025
ISIN: GB00B0LCW083
Hikma Pharmaceuticals PLC
HIK
LISTED
LSE
Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines
Article
News Preview
Next phase builds on 34+ years of serving the needs of US patients and healthcare providers COLUMBUS, Ohio, June 28, 2025 /PRNewswire/ -- In its ongoing mission to help meet America's growing need for high-quality US-made medicines, Hikma Pharmaceuticals USA today announces it will invest $1 billion by 2030 to further expand its US manufacturing...
Themefolio
Profiler
Peergroup
© PR Newswire
28.06.2025
ISIN: SE0000872095
Swedish Orphan Biovitrum AB (publ)
SOBI
LISTED
STO
FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease
Article
News Preview
Approval based on the pooled analysis of our pivotal EMERALD and NI-0501-06 studies, showing 54% of patients treated with Gamifant achieved complete response at week 8.STOCKHOLM, June 28, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that the U.S. Food and Drug Administration (FDA) approved Gamifant® (emapalumab-lzsg) for the treatment o...
Themefolio
Profiler
Peergroup
© PR Newswire
28.06.2025
ISIN: SE0000872095
Swedish Orphan Biovitrum AB (publ)
SOBI
LISTED
STO
FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease
Article
News Preview
Approval based on the pooled analysis of our pivotal EMERALD and NI-0501-06 studies, showing 54% of patients treated with Gamifant achieved complete response at week 8.STOCKHOLM, June 28, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that the U.S. Food and Drug Administration (FDA) approved Gamifant® (emapalumab-lzsg) for the treatment o...
Themefolio
Profiler
Peergroup
© BusinessWire
27.06.2025
ISIN: US88023B1035
Tempus AI, Inc.
TEM
LISTED
NASDAQ
Deadline Alert: Tempus AI, Inc. (TEM) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Article
News Preview
Glancy Prongay & Murray LLP reminds investors of the upcoming August 12, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”...
Themefolio
Profiler
Peergroup
© EQS Newswire
27.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon increases bond volume following oversubscription – Bond 2025/2029 with a volume of EUR 70 million successfully and entirely placed
Article
News Preview
Press Release // 27. June 2025  Formycon increases bond volume following oversubscription – Bond 2025/2029 with a volume of EUR 70 million successfully and entirely placed Due to strong demand, the offering period for the public offering has been shortened and target volume was increased from initially EUR 50 million to EUR 70 million Interest ......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon erhöht Anleihevolumen nach Überzeichnung – Anleihe 2025/2029 in Höhe von 70 Mio. Euro erfolgreich und vollständig platziert
Article
News Preview
Pressemitteilung // 27. Juni 2025 Formycon erhöht Anleihevolumen nach Überzeichnung – Anleihe 2025/2029 in Höhe von 70 Mio. Euro erfolgreich und vollständig platziert Aufgrund starker Nachfrage Angebotszeitraum des öffentlichen Angebots verkürzt und Zielvolumen von ursprünglich 50 Mio. Euro auf 70 Mio. Euro erhöht Zinssatz in Höhe des EURIBOR pl......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon successfully places an EUR 70 million senior unsecured floating rate bond
Article
News Preview
Disclosure of Inside Information Pursuant to Article 17 of Regulation (EU) No. 596/2014 NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR PUBLICATION MAY BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE ......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon platziert erfolgreich eine unbesicherte und variabel verzinsliche Anleihe in Höhe von EUR 70 Mio.
Article
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014 NICHT ZUR VERBREITUNG, VERÖFFENTLICHUNG ODER WEITERGABE, DIREKT ODER INDIREKT, IN ODER INNERHALB DER VEREINIGTEN STAATEN VON AMERIKA, KANADA, AUSTRALIEN, JAPAN ODER ANDEREN LÄNDERN, IN DENEN DIE VERBREITUNG ODER VERÖFFENTLICHUNG RECHTSWIDRIG SEIN KÖNNTE. ES ......
Themefolio
Profiler
Peergroup
© Globe Newswire
27.06.2025
ISIN: SE0002190926
Karolinska Development AB
KDEV
LISTED
STO
Karolinska Development's portfolio company Modus Therapeutics carries out a fully secured rights issue of SEK 28.3 million
Article
News Preview
STOCKHOLM, SWEDEN June 27, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics carries out a fully secured rights issue of units of SEK 28.3 million. The proceeds from the rights issue are intended to finance the continued development of the drug candidate sevuparin in chronic kidn...
Themefolio
Profiler
Peergroup
© PR Newswire
27.06.2025
ISIN: SE0000135485
RaySearch Laboratories AB (publ)
RAY B
LISTED
STO
RaySearch releases RayCare v2025
Article
News Preview
STOCKHOLM, June 27, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces the release of RayCare®* v2025, the latest version of its next-generation oncology information system. The new release delivers powerful functionality enhancements that streamline clinical workflows, improve data management, and strengthen interoperability across...
Themefolio
Profiler
Peergroup
© BusinessWire
26.06.2025
ISIN: US88023B1035
Tempus AI, Inc.
TEM
LISTED
NASDAQ
Deadline Approaching: Tempus AI, Inc. (TEM) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Article
News Preview
Law Offices of Howard G. Smith reminds investors of the upcoming August 12, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO...
Themefolio
Profiler
Peergroup
© PR Newswire
26.06.2025
ISIN: SE0010323311
BioArctic AB
BIOA B
LISTED
STO
BioArctic: Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize
Article
News Preview
STOCKHOLM, June 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that BioArctic's founder, Professor Lars Lannfelt, will receive the 2025 Hartwig Piepenbrock-DZNE Prize for his pioneering contributions to the understanding of Alzheimer's disease and to the development of the drug lecanemab. The prize is pres...
Themefolio
Profiler
Peergroup
© PR Newswire
26.06.2025
ISIN: SE0010323311
BioArctic AB
BIOA B
LISTED
STO
BioArctic: Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize
Article
News Preview
STOCKHOLM, June 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that BioArctic's founder, Professor Lars Lannfelt, will receive the 2025 Hartwig Piepenbrock-DZNE Prize for his pioneering contributions to the understanding of Alzheimer's disease and to the development of the drug lecanemab. The prize is pres...
Themefolio
Profiler
Peergroup
© EQS Newswire
26.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Teva wird Zweitvermarktungspartner für Formycons Stelara®-Biosimilar FYB202 (Ustekinumab) unter der Marke Fymskina® in Deutschland
Article
News Preview
Pressemitteilung // 26. Juni 2025   Teva wird Zweitvermarktungspartner für Formycons Stelara®-Biosimilar FYB202 (Ustekinumab) unter der Marke Fymskina® in Deutschland   Teva-Tochter Ratiopharm vermarktet Fymskina® als weiteres Formycon Ustekinumab-Biosimilar semi-exklusiv in Deutschland Markteinführung von Fymskina® für das 3. Quartal 2025 gepl......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Teva becomes secondary commercialization partner for Formycon's Stelara® biosimilar FYB202 (ustekinumab) under the brand name Fymskina® in Germany
Article
News Preview
Press Release // June 26, 2025   Teva becomes secondary commercialization partner for Formycon's Stelara® biosimilar FYB202 (ustekinumab) under the brand name Fymskina® in Germany   Teva's subsidiary Ratiopharm is going to commercialize Fymskina® as a second Formycon ustekinumab biosimilar on a semi-exclusive basis in Germany Market launch of F......
Themefolio
Profiler
Peergroup
© Globe Newswire
26.06.2025
ISIN: DK0015998017
Bavarian Nordic A/S
BAVA
LISTED
CPH
Bavarian Nordic Announces the Initiation of Clinical Trials of Mpox Vaccine in Infants and Pregnant Women
Article
News Preview
COPENHAGEN, Denmark, June 26, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of the first of two clinical trials designed to support approval and use of the MVA-BN® mpox/smallpox vaccine in vulnerable populations: infants under 2 years of age and pregnant and breastfeeding women...
Themefolio
Profiler
Peergroup
© BusinessWire
25.06.2025
ISIN: US88023B1035
Tempus AI, Inc.
TEM
LISTED
NASDAQ
Ambry Genetics’ CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing
Article
News Preview
Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM) company and a leader in clinical genomic testing, announced today that a peer-reviewed study validating the accuracy of the Ambry CARE Program® (CARE) for hereditary cancer risk assessment has been published in the Journal of the National Comprehensive Cancer Network. T...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2025
ISIN: FR0010417345
Dbv Technologies SA
DBV
LISTED
EURONEXT
DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old
Article
News Preview
Châtillon, France, June 25, 2025...
Themefolio
Profiler
Peergroup
© ActuNews
25.06.2025
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
Article
News Preview
Leuven, BELGIUM – June 25, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on June 23, 2025, from Atlas...
Themefolio
Profiler
Peergroup
© ActuNews
25.06.2025
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC
Article
News Preview
Leuven, BELGIË – 25 juni 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen: Oxurion ontving een transparanti...
Themefolio
Profiler
Peergroup
© PR Newswire
25.06.2025
ISIN: SE0015661152
Hamlet Biopharma AB (B)
HAMLET B
LISTED
STO
Hamlet BioPharma Holds Successful In Person Meeting with US FDA
Article
News Preview
LUND, Sweden, June 25, 2025 /PRNewswire/ -- Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, today announces the successful first in-person meeting with the U.S. Food and Drug Administration (FDA). The meeting was held on June 24, 2025. The 'take home message' from the discussion wa...
Themefolio
Profiler
Peergroup
© BusinessWire
25.06.2025
ISIN: FR0014000MR3
Eurofins Scientific SE
ERF
LISTED
EURONEXT
Eurofins Scientific: Director/PDMR Shareholding
Article
News Preview
Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF T...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2025
ISIN: US03168L1052
Amneal Pharmaceuticals Inc
AMRX
LISTED
NASDAQ
Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences
Article
News Preview
Amneal holds exclusive U.S. commercialization rights; BLA filing expected in Q4 2025...
Themefolio
Profiler
Peergroup
© EQS Newswire
25.06.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotecs Partnerschaft mit dem NURTuRE-AKI Konsortium ermöglicht innovative therapeutische Ansätze basierend auf molekularem Verständnis von akutem Nierenversagen
Article
News Preview
  NURTuRE-AKI ist eine neue Beobachtungsstudie, die longitudinale biologische Proben und klinische Daten von Patienten mit akutem Nierenversagen (Acute Kidney Injury, „AKI") sammelt. Sie wurde im Rahmen eines Forschungskonsortiums unter Leitung von Kidney Research UK entwickelt. Die Studie konzentriert sich auf 3 Kohorten: AKI nach Herzop......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.06.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec joins NURTuRE-AKI consortium to gain multi-omics-based molecular understanding of acute kidney injury
Article
News Preview
  NURTuRE-AKI is a novel observational study that collects longitudinal data and biological samples from fully consented acute kidney injury (“AKI”) patients, developed as part of a research consortium led by Kidney Research UK The study focuses on 3 clearly defined cohorts: AKI of iatrogenic origin (following cardiac surgery), AKI to chr......
Themefolio
Profiler
Peergroup
© Newsfile
25.06.2025
ISIN: NL0011832936
Cosmo Pharmaceuticals NV
COPN
LISTED
SIX
Cosmo Announces Sale of "Digital Trust" in Strategic Portfolio Streamlining Move
Article
News Preview
Dublin, Ireland--(Newsfile Corp. - June 25, 2025) - Cosmo today announced the signing of an agreement to sell “Digital Trust” to its existing customer Tinexta InfoCert, Europe’s largest Certification Authority and a subsidiary of Tinexta S.p.A., a publicly listed company in Italy. The transaction is expected to close by...
Themefolio
Profiler
Peergroup
© EQS Newswire
25.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
US-Biosimilarspezialist Valorum Biologics LLC wird Kommerzialisierungspartner für Formycons Eylea®-Biosimilar FYB203/AHZANTIVE® (Aflibercept-mrbb) in den Vereinigten Staaten und Kanada
Article
News Preview
Pressemitteilung // 25. Juni 2025   US-Biosimilarspezialist Valorum Biologics LLC wird Kommerzialisierungspartner für Formycons Eylea®-Biosimilar FYB203/AHZANTIVE® (Aflibercept-mrbb) in den Vereinigten Staaten und Kanada  Valorum Biologics, US-Biosimilar-Spezialist mit Fokus auf Augenheilkunde und Onkologie wird FYB203/AHZANTIVE® exklusiv in den ......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® (aflibercept-mrbb) in the United States and Canada
Article
News Preview
Press Release // June 25, 2025   U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® (aflibercept-mrbb) in the United States and Canada   Valorum Biologics, an expert for ophthalmology and oncology biosimilars in the U.S. market, will exclusively commercialize FYB20......
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics provides an update on ongoing proceedings
Article
News Preview
OSE Immunotherapeutics provides an update on ongoing proceedings...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
25.06.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury
Article
News Preview
NURTuRE-AKI is a novel observational study that collects longitudinal data and biological samples from fully consented acute kidney injury ("AKI") patients, developed as part of a research consortium led by Kidney Research UKThe study focuses on 3 clearly defined cohorts: AKI of iatrogenic origin (following cardiac surgery), AKI to chroni...
Themefolio
Profiler
Peergroup
© PR Newswire
24.06.2025
ISIN: GB00BN4HT335
Indivior PLC
INDV
LISTED
NASDAQ
Indivior Appoints Tony Kingsley to the Board of Directors
Article
News Preview
RICHMOND, Va., June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as an Independent Non-Executive Director, effective July 1, 2025. Mr. Kingsley was appointed pursuant to Indivior's relationship agreement with affiliates of Oaktree Capital Management, L.P., wh...
Themefolio
Profiler
Peergroup
© EQS Newswire
24.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Starke Nachfrage nach Formycon-Anleihe 2025/2029 führt zu Verkürzung der Angebotsfrist
Article
News Preview
Pressemitteilung // 24. Juni 2025 Starke Nachfrage nach Formycon-Anleihe 2025/2029 führt zu Verkürzung der Angebotsfrist Hohe Nachfrage institutioneller Investoren ermöglicht vorzeitiges Ende des öffentlichen Angebotszeitraums Zeichnungsfrist über die Formycon-Webseite endet bereits am 26. Juni 2025, 23:59 Uhr MESZ Zeichnung über DirectPlace de......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period
Article
News Preview
  Press Release // June 24, 2025 Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period High demand by institutional investors enables early termination of public offering period Subscription period via the Formycon website is now scheduled to end  on 26 June 2025, at 11:59 p.m. CEST Subscription via Deutsche B......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.06.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Vorzeitiges Ende der Angebotsfrist für Anleihe aufgrund hoher Nachfrage
Article
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014 NICHT ZUR VERBREITUNG, VERÖFFENTLICHUNG ODER WEITERGABE, DIREKT ODER INDIREKT, IN ODER INNERHALB DER VEREINIGTEN STAATEN VON AMERIKA, KANADA, AUSTRALIEN, JAPAN ODER ANDEREN LÄNDERN, IN DENEN DIE VERBREITUNG ODER VERÖFFENTLICHUNG RECHTSWIDRIG SEIN KÖNNTE. ES ......
Themefolio
Profiler
Peergroup
© BusinessWire
24.06.2025
ISIN: US88023B1035
Tempus AI, Inc.
TEM
LISTED
NASDAQ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Tempus AI, Inc. (TEM) Investors To Inquire About Securities Fraud Class Action
Article
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the “Class Perio...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Monday, 19.01.2026, Calendar Week 04, 19th day of the year, 346 days remaining until EoY.